[
  {
    "title": "奥翔药业(603229.SZ)：拟使用不超2亿元闲置募集资金暂补流动资金",
    "href": "http://stock.jrj.com.cn/2022/12/26153737237958.shtml",
    "datetime": "2022-12-26 15:37:57",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：控股股东、董高暨持股平台完成减持合计5.06%股份",
    "href": "http://stock.jrj.com.cn/2022/12/21191837229270.shtml",
    "datetime": "2022-12-21 19:18:06",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：实控人郑志国合计减持1.43%股份",
    "href": "http://stock.jrj.com.cn/2022/12/21191537229276.shtml",
    "datetime": "2022-12-21 19:15:03",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：减持数过半 控股股东郑志国累计减持2.57%股份",
    "href": "http://stock.jrj.com.cn/2022/12/14191137212847.shtml",
    "datetime": "2022-12-14 19:11:30",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业12月14日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/12/14181437212581.shtml",
    "datetime": "2022-12-14 18:14:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)第三季度净利润5405.42万元 同比增长95.65%",
    "href": "http://stock.jrj.com.cn/2022/10/30171937097413.shtml",
    "datetime": "2022-10-30 17:19:39",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：获批非公开发行不超4018.667万股新股",
    "href": "http://stock.jrj.com.cn/2022/09/30173137034453.shtml",
    "datetime": "2022-09-30 17:31:04",
    "code": "603229"
  },
  {
    "title": "奥翔药业：非公开发行股票申请获审核通过",
    "href": "http://stock.jrj.com.cn/2022/09/05161836973854.shtml",
    "datetime": "2022-09-05 16:18:17",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：定增申请获证监会审核通过",
    "href": "http://stock.jrj.com.cn/2022/09/05161436973862.shtml",
    "datetime": "2022-09-05 16:14:22",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)半年度净利润1.23亿元、同比增长48.78%",
    "href": "http://stock.jrj.com.cn/2022/08/29222636949510.shtml",
    "datetime": "2022-08-29 22:26:52",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业8月1日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/08/01180636859967.shtml",
    "datetime": "2022-08-01 18:06:43",
    "code": "603229"
  },
  {
    "title": "奥翔药业四连跌停！网友：韭菜根都拔了",
    "href": "http://stock.jrj.com.cn/2022/07/31144336856511.shtml",
    "datetime": "2022-07-31 14:43:00",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业7月29日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/07/29180536854581.shtml",
    "datetime": "2022-07-29 18:05:53",
    "code": "603229"
  },
  {
    "title": "【互动】奥翔药业：子公司麒正药业与真实生物签订协议目前并未失效",
    "href": "http://stock.jrj.com.cn/2022/07/29133736853386.shtml",
    "datetime": "2022-07-29 13:37:43",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业7月28日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/07/28180736851141.shtml",
    "datetime": "2022-07-28 18:07:33",
    "code": "603229"
  },
  {
    "title": "突发！2万亿赛道大爆发，涨停潮！两天翻倍，这只产品涨疯了",
    "href": "http://stock.jrj.com.cn/2022/07/28125836849976.shtml",
    "datetime": "2022-07-28 12:58:45",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：麒正药业仅为真实生物阿兹夫定片的受托加工生产企业",
    "href": "http://stock.jrj.com.cn/2022/07/27183436847735.shtml",
    "datetime": "2022-07-27 18:34:06",
    "code": "603229"
  },
  {
    "title": "奥翔药业：子公司麒正药业仅为真实生物的受托加工生产企业",
    "href": "http://stock.jrj.com.cn/2022/07/27182636847692.shtml",
    "datetime": "2022-07-27 18:26:12",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：西他沙星原料药通过CDE技术审评",
    "href": "http://stock.jrj.com.cn/2022/07/26182136844392.shtml",
    "datetime": "2022-07-26 18:21:14",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：LAV Bridge拟减持不超490.5477万股",
    "href": "http://stock.jrj.com.cn/2022/07/26181936844350.shtml",
    "datetime": "2022-07-26 18:19:45",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业7月26日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/07/26180636844304.shtml",
    "datetime": "2022-07-26 18:06:04",
    "code": "603229"
  },
  {
    "title": "新冠药物板块高开低走，奥翔药业触及跌停",
    "href": "http://stock.jrj.com.cn/2022/07/26094036842617.shtml",
    "datetime": "2022-07-26 09:40:07",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业7月15日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/07/15180636816613.shtml",
    "datetime": "2022-07-15 18:06:53",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：486.6万股限售股将于6月21日解禁上市",
    "href": "http://stock.jrj.com.cn/2022/06/15175636731758.shtml",
    "datetime": "2022-06-15 17:56:47",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：舒更葡糖钠原料药通过CDE技术审评",
    "href": "http://stock.jrj.com.cn/2022/06/07181336709855.shtml",
    "datetime": "2022-06-07 18:13:36",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业5月31日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/05/31180536693857.shtml",
    "datetime": "2022-05-31 18:05:51",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业5月20日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/05/20180636666501.shtml",
    "datetime": "2022-05-20 18:06:24",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：2021年度权益分派10转4派1.02元 股权登记日为5月25日",
    "href": "http://stock.jrj.com.cn/2022/05/19164636662492.shtml",
    "datetime": "2022-05-19 16:46:02",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业5月16日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/05/16180736652080.shtml",
    "datetime": "2022-05-16 18:07:24",
    "code": "603229"
  },
  {
    "title": "A股异动 | 奥翔药业涨8% 子公司已就阿兹夫定片加工生产与真实生物签订相关协议",
    "href": "http://stock.jrj.com.cn/2022/05/11093836630572.shtml",
    "datetime": "2022-05-11 09:38:36",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：子公司日前已就阿兹夫定片的加工生产与真实生物签订委托加工生产框架协议等等",
    "href": "http://stock.jrj.com.cn/2022/05/10190736622783.shtml",
    "datetime": "2022-05-10 19:07:56",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：非公开发行A股股票申请获证监会受理",
    "href": "http://stock.jrj.com.cn/2022/05/09174536607768.shtml",
    "datetime": "2022-05-09 17:45:05",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业5月6日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/05/06180936581864.shtml",
    "datetime": "2022-05-06 18:09:02",
    "code": "603229"
  },
  {
    "title": "奥翔药业减持与增发要趁早",
    "href": "http://stock.jrj.com.cn/2022/04/22151536428112.shtml",
    "datetime": "2022-04-22 15:15:45",
    "code": "603229"
  },
  {
    "title": "A股异动 | 奥翔药业(603229.SZ)盘中涨停 绩后获券商唱好",
    "href": "http://stock.jrj.com.cn/2022/04/21101636416412.shtml",
    "datetime": "2022-04-21 10:16:45",
    "code": "603229"
  },
  {
    "title": "奥翔药业2021年净利1.46亿同比增长68.05% 董事长郑志国薪酬85.39万",
    "href": "http://stock.jrj.com.cn/2022/04/20201236412227.shtml",
    "datetime": "2022-04-20 20:12:38",
    "code": "603229"
  },
  {
    "title": "奥翔药业2022年第一季度净利7072.26万同比增长61.18% 国际业务增长",
    "href": "http://stock.jrj.com.cn/2022/04/20093236406894.shtml",
    "datetime": "2022-04-20 09:32:55",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)一季度净利润7072.26万元 同比增长61.18%",
    "href": "http://stock.jrj.com.cn/2022/04/19195236401918.shtml",
    "datetime": "2022-04-19 19:52:11",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)2021年度净利润升68.05%至1.46亿元 拟10转4派1.02元",
    "href": "http://stock.jrj.com.cn/2022/04/19195236401919.shtml",
    "datetime": "2022-04-19 19:52:02",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：目前尚无新冠药物相关产品",
    "href": "http://stock.jrj.com.cn/2022/04/13184036325942.shtml",
    "datetime": "2022-04-13 18:40:49",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业4月13日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/04/13180436325391.shtml",
    "datetime": "2022-04-13 18:04:45",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：控股股东、董事、高管暨持股平台拟合计减持不超1571.848万股",
    "href": "http://stock.jrj.com.cn/2022/04/06220336264899.shtml",
    "datetime": "2022-04-06 22:03:57",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：子公司麒正药业获得药品生产许可证",
    "href": "http://stock.jrj.com.cn/2022/03/28153835874261.shtml",
    "datetime": "2022-03-28 15:38:01",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业3月21日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/03/21180634856623.shtml",
    "datetime": "2022-03-21 18:06:10",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业3月15日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/03/15180334830057.shtml",
    "datetime": "2022-03-15 18:03:30",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)拟定增募资不超5亿元 用于高端制剂国际化项目(一期)等",
    "href": "http://stock.jrj.com.cn/2022/03/08172534541704.shtml",
    "datetime": "2022-03-08 17:25:11",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：拟以3500万元参投上海以康二期",
    "href": "http://stock.jrj.com.cn/2022/03/07153634537590.shtml",
    "datetime": "2022-03-07 15:36:21",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：公司目前尚无新冠药物相关产品",
    "href": "http://stock.jrj.com.cn/2022/03/01230934509855.shtml",
    "datetime": "2022-03-01 23:09:44",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业3月1日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/03/01180434508922.shtml",
    "datetime": "2022-03-01 18:04:51",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业2月11日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/02/11180634324273.shtml",
    "datetime": "2022-02-11 18:06:44",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业2月7日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/02/07180634302475.shtml",
    "datetime": "2022-02-07 18:06:55",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业1月27日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/01/27180634231341.shtml",
    "datetime": "2022-01-27 18:06:31",
    "code": "603229"
  },
  {
    "title": "A股异动 | 奥翔药业(603229.SZ)涨停 料年度净利同比增50.86%至70.44%",
    "href": "http://stock.jrj.com.cn/2022/01/20095234177098.shtml",
    "datetime": "2022-01-20 09:52:31",
    "code": "603229"
  },
  {
    "title": "奥翔药业2021年预计净利1.31亿-1.48亿增长51%-70.44% 特色原料药业务取得较快增长",
    "href": "http://stock.jrj.com.cn/2022/01/19201234175402.shtml",
    "datetime": "2022-01-19 20:12:09",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)2021年度净利润预增50.86%-70.44%",
    "href": "http://stock.jrj.com.cn/2022/01/19172534174558.shtml",
    "datetime": "2022-01-19 17:25:00",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业1月14日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/01/14180734158507.shtml",
    "datetime": "2022-01-14 18:07:01",
    "code": "603229"
  },
  {
    "title": "奥翔药业：聘任应晓晨为董事会秘书",
    "href": "http://stock.jrj.com.cn/2021/12/24212434123019.shtml",
    "datetime": "2021-12-24 21:24:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：拟使用不超2亿元闲置募集资金暂补流动资金",
    "href": "http://stock.jrj.com.cn/2021/12/24154034057772.shtml",
    "datetime": "2021-12-24 15:40:17",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：拟使用不超1.6亿元闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2021/12/24153934057767.shtml",
    "datetime": "2021-12-24 15:39:08",
    "code": "603229"
  },
  {
    "title": "A股异动 | 奥翔药业(603229.SZ)跌超6% 股东拟减持不超4.91%股份",
    "href": "http://stock.jrj.com.cn/2021/11/25093633917576.shtml",
    "datetime": "2021-11-25 09:36:31",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：股东LAV Bridge及其一致行动人拟减持合计不超4.91%股份",
    "href": "http://stock.jrj.com.cn/2021/11/24181233915003.shtml",
    "datetime": "2021-11-24 18:12:25",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业11月11日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/11/11180633837157.shtml",
    "datetime": "2021-11-11 18:06:33",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业11月10日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/11/10180433832471.shtml",
    "datetime": "2021-11-10 18:04:52",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：与STADA签订合作开发和商业化战略合作协议",
    "href": "http://stock.jrj.com.cn/2021/11/04184033813644.shtml",
    "datetime": "2021-11-04 18:40:12",
    "code": "603229"
  },
  {
    "title": "奥翔药业：与STADA Arzneimittel AG签订《合作开发和商业化战略合作协议》",
    "href": "http://stock.jrj.com.cn/2021/11/04173933813303.shtml",
    "datetime": "2021-11-04 17:39:15",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SZ)：聘任朱丁敏为财务总监",
    "href": "http://stock.jrj.com.cn/2021/11/04173733813302.shtml",
    "datetime": "2021-11-04 17:37:26",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：第三季度净利增103.28%至2762.797万元",
    "href": "http://stock.jrj.com.cn/2021/10/25170633747862.shtml",
    "datetime": "2021-10-25 17:06:52",
    "code": "603229"
  },
  {
    "title": "奥翔药业2021年半年度净利8268.55万元 同比净利增加57.20%",
    "href": "http://stock.jrj.com.cn/2021/08/17181733268015.shtml",
    "datetime": "2021-08-17 18:17:45",
    "code": "603229"
  },
  {
    "title": "奥翔药业半年报：上半年净利8268.55万元 同比增长57%",
    "href": "http://stock.jrj.com.cn/2021/08/17164133267165.shtml",
    "datetime": "2021-08-17 16:41:14",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：上半年净利增57.20%至8268.55万元",
    "href": "http://stock.jrj.com.cn/2021/08/17163833267145.shtml",
    "datetime": "2021-08-17 16:38:16",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业7月5日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/07/05180733048245.shtml",
    "datetime": "2021-07-05 18:07:01",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：2020年度权益分派10转2派0.75元 股权登记日7月5日",
    "href": "http://stock.jrj.com.cn/2021/06/28222533012218.shtml",
    "datetime": "2021-06-28 22:25:18",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：1230.99万股限售股6月21日解禁",
    "href": "http://stock.jrj.com.cn/2021/06/15174532935417.shtml",
    "datetime": "2021-06-15 17:45:54",
    "code": "603229"
  },
  {
    "title": "奥翔药业：自上市以来公司每年研发投入占营业收入比重均超过10%",
    "href": "http://stock.jrj.com.cn/2021/04/30095332485040.shtml",
    "datetime": "2021-04-30 09:53:14",
    "code": "603229"
  },
  {
    "title": "奥翔药业2020年净利增长54% 董事长郑志国薪酬60.9164万",
    "href": "http://stock.jrj.com.cn/2021/04/29101532478394.shtml",
    "datetime": "2021-04-29 10:15:18",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)一季度净利润4387.8万元 同比增长109.15%",
    "href": "http://stock.jrj.com.cn/2021/04/27213232465603.shtml",
    "datetime": "2021-04-27 21:32:30",
    "code": "603229"
  },
  {
    "title": "奥翔药业：公司全资子公司浙江麒正药业有限公司预计总投资49100万元新建国际化制剂产业基地项目",
    "href": "http://stock.jrj.com.cn/2021/04/26133732453418.shtml",
    "datetime": "2021-04-26 13:37:19",
    "code": "603229"
  },
  {
    "title": "奥翔药业：该项目资金来源为自有资金及银行贷款",
    "href": "http://stock.jrj.com.cn/2021/04/06084132317142.shtml",
    "datetime": "2021-04-06 08:41:09",
    "code": "603229"
  },
  {
    "title": "奥翔药业：拟5000万元增资麒正药业 有助于进一步推进其业务发展",
    "href": "http://stock.jrj.com.cn/2021/03/26163932223097.shtml",
    "datetime": "2021-03-26 16:39:16",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：与Stada Arzneimittel AG签订产品开发和商业化临时合作协议",
    "href": "http://stock.jrj.com.cn/2021/03/26155032222789.shtml",
    "datetime": "2021-03-26 15:50:13",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：子公司拟投资新建国际化制剂产业基地项目(一期)",
    "href": "http://stock.jrj.com.cn/2021/03/26153732222705.shtml",
    "datetime": "2021-03-26 15:37:17",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)拟向麒正药业增资5000万元",
    "href": "http://stock.jrj.com.cn/2021/03/26153632222701.shtml",
    "datetime": "2021-03-26 15:36:53",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：8835万元竞得浙江头门港经济开发区一宗工业用地",
    "href": "http://stock.jrj.com.cn/2021/01/20153931728841.shtml",
    "datetime": "2021-01-20 15:39:09",
    "code": "603229"
  },
  {
    "title": "奥翔药业2020年预计净利8500万-9600万 特色原料药业务取得较快增长",
    "href": "http://stock.jrj.com.cn/2021/01/13211631686413.shtml",
    "datetime": "2021-01-13 21:16:46",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：2020年度净利预增50.74%到70.24%",
    "href": "http://stock.jrj.com.cn/2021/01/13184331685590.shtml",
    "datetime": "2021-01-13 18:43:12",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：拟使用最高额不超1.8亿元闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2020/12/24160131561649.shtml",
    "datetime": "2020-12-24 16:01:58",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)拟使用不超2亿元闲置募集资金暂补流动资金",
    "href": "http://stock.jrj.com.cn/2020/12/24155131561560.shtml",
    "datetime": "2020-12-24 15:51:37",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：LAV Bridge及一致行动人合计持股比例跌出5%",
    "href": "http://stock.jrj.com.cn/2020/12/22181231546434.shtml",
    "datetime": "2020-12-22 18:12:23",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：控股股东持股比例下降2.61%",
    "href": "http://stock.jrj.com.cn/2020/12/22181031546414.shtml",
    "datetime": "2020-12-22 18:10:35",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：拟斥不超9000万元买地 作CDMO等业务储备用地",
    "href": "http://stock.jrj.com.cn/2020/12/14173231487893.shtml",
    "datetime": "2020-12-14 17:32:05",
    "code": "603229"
  },
  {
    "title": "奥翔药业：为进一步扩大医药产业布局 奥翔香港拟出资200万美元认购英派药业1%股权",
    "href": "http://stock.jrj.com.cn/2020/11/27204131362728.shtml",
    "datetime": "2020-11-27 20:41:22",
    "code": "603229"
  },
  {
    "title": "奥翔药业前三季度净利6618.9万增长31.64% 收到政府补助增加",
    "href": "http://stock.jrj.com.cn/2020/10/30222431177355.shtml",
    "datetime": "2020-10-30 22:24:16",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业10月30日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/10/30180431176214.shtml",
    "datetime": "2020-10-30 18:04:13",
    "code": "603229"
  },
  {
    "title": "奥翔药业(603229.SH)：前三季度净利升31.64%至6618.90万元",
    "href": "http://stock.jrj.com.cn/2020/10/30114131174492.shtml",
    "datetime": "2020-10-30 11:41:09",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2020年前三季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/10/30004031161743.shtml",
    "datetime": "2020-10-30 00:40:11",
    "code": "603229"
  },
  {
    "title": "奥翔药业：前三季度净利润6618.90万元 同比增长逾三成",
    "href": "http://stock.jrj.com.cn/2020/10/29174131158470.shtml",
    "datetime": "2020-10-29 17:41:08",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第二十一次会议决议公告",
    "href": "http://stock.jrj.com.cn/2020/09/11135030729275.shtml",
    "datetime": "2020-09-11 13:50:02",
    "code": "603229"
  },
  {
    "title": "IPO项目3年推进缓慢却重启定增 资金充裕的奥翔药业搞啥名堂？",
    "href": "http://stock.jrj.com.cn/2020/08/13071830488061.shtml",
    "datetime": "2020-08-13 07:18:45",
    "code": "603229"
  },
  {
    "title": "[奥翔药业]中国证监会投资者维权渠道介绍",
    "href": "http://stock.jrj.com.cn/2020/08/07000030451792.shtml",
    "datetime": "2020-08-07 00:00:00",
    "code": "603229"
  },
  {
    "title": "不符合监管新要求 奥翔药业终止定增方案重新申报",
    "href": "http://stock.jrj.com.cn/2020/07/27074730350870.shtml",
    "datetime": "2020-07-27 07:47:32",
    "code": "603229"
  },
  {
    "title": "奥翔药业上半年扣非净利同比增近八成 原料药行业或将再步入景气周期",
    "href": "http://stock.jrj.com.cn/2020/07/20024030284917.shtml",
    "datetime": "2020-07-20 02:40:03",
    "code": "603229"
  },
  {
    "title": "奥翔药业扣非净利润增近八成 研发投入增1.2倍 业绩高增将继续",
    "href": "http://stock.jrj.com.cn/2020/07/17083330271921.shtml",
    "datetime": "2020-07-17 08:33:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业聘任钟瑜为副总经理、李震宇为董事会秘书兼财务总监",
    "href": "http://stock.jrj.com.cn/2020/07/16194730263418.shtml",
    "datetime": "2020-07-16 19:47:52",
    "code": "603229"
  },
  {
    "title": "奥翔药业2020年上半年净利5259.8万增长69.46% 产品销售收入增加",
    "href": "http://stock.jrj.com.cn/2020/07/16194530263378.shtml",
    "datetime": "2020-07-16 19:45:58",
    "code": "603229"
  },
  {
    "title": "奥翔药业上半年净利同比增长近七成",
    "href": "http://stock.jrj.com.cn/2020/07/16173630262631.shtml",
    "datetime": "2020-07-16 17:36:10",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业7月13日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2020/07/13180930226857.shtml",
    "datetime": "2020-07-13 18:09:40",
    "code": "603229"
  },
  {
    "title": "快讯：奥翔药业急速拉升6.00% 主力资金净流出122.22万元(dev)",
    "href": "http://stock.jrj.com.cn/2020/06/24100130007337.shtml",
    "datetime": "2020-06-24 10:01:13",
    "code": "603229"
  },
  {
    "title": "快讯：奥翔药业急速拉升8.15% 主力资金净流出3954.44万元(dev)",
    "href": "http://stock.jrj.com.cn/2020/06/23131629998186.shtml",
    "datetime": "2020-06-23 13:16:01",
    "code": "603229"
  },
  {
    "title": "奥翔药业副总经理、财务总监娄杭辞职 2019年薪酬为28.78万元",
    "href": "http://stock.jrj.com.cn/2020/06/16214029941050.shtml",
    "datetime": "2020-06-16 21:40:33",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2019年年度权益分派实施公告",
    "href": "http://stock.jrj.com.cn/2020/06/16001129931134.shtml",
    "datetime": "2020-06-16 00:11:10",
    "code": "603229"
  },
  {
    "title": "【龙虎榜】奥翔药业5月18日成交明细(dev)",
    "href": "http://stock.jrj.com.cn/2020/05/18180729703934.shtml",
    "datetime": "2020-05-18 18:07:25",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2019年年度股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/05/12232029653897.shtml",
    "datetime": "2020-05-12 23:20:04",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2020年第一次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/05/12005029644747.shtml",
    "datetime": "2020-05-12 00:50:02",
    "code": "603229"
  },
  {
    "title": "奥翔药业第一季度盈利2097.96万同比增长169.59% 汇兑收益增加",
    "href": "http://stock.jrj.com.cn/2020/04/30170629432372.shtml",
    "datetime": "2020-04-30 17:06:44",
    "code": "603229"
  },
  {
    "title": "奥翔药业：关于召开2020年第一次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2020/04/25051029372021.shtml",
    "datetime": "2020-04-25 05:10:17",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第十五次会议决议公告",
    "href": "http://stock.jrj.com.cn/2020/04/25051029372020.shtml",
    "datetime": "2020-04-25 05:10:17",
    "code": "603229"
  },
  {
    "title": "奥翔药业拟定增募资不超3.5亿元 用于特色原料药及关键医药中间体生产基地建设项目",
    "href": "http://stock.jrj.com.cn/2020/04/24215429369912.shtml",
    "datetime": "2020-04-24 21:54:59",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2019年年度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/04/03011029180500.shtml",
    "datetime": "2020-04-03 01:10:12",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第十四次会议决议公告",
    "href": "http://stock.jrj.com.cn/2020/04/03011029180501.shtml",
    "datetime": "2020-04-03 01:10:12",
    "code": "603229"
  },
  {
    "title": "奥翔药业：关于召开2019年年度股东大会的通知",
    "href": "http://stock.jrj.com.cn/2020/04/03011029180502.shtml",
    "datetime": "2020-04-03 01:10:12",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2019年净利同比增29% 拟10转4派0.75元",
    "href": "http://stock.jrj.com.cn/2020/04/02155429177222.shtml",
    "datetime": "2020-04-02 15:54:00",
    "code": "603229"
  },
  {
    "title": "[奥翔药业]疫情期间,防疫通知",
    "href": "http://stock.jrj.com.cn/2020/02/28000029748295.shtml",
    "datetime": "2020-02-28 00:00:00",
    "code": "603229"
  },
  {
    "title": "佛山系游资翘板创力集团 机构敢冒风险接盘奥翔药业",
    "href": "http://stock.jrj.com.cn/2019/12/10071828511822.shtml",
    "datetime": "2019-12-10 07:18:27",
    "code": "603229"
  },
  {
    "title": "奥翔药业跌停 两机构席位买入逾4000万元",
    "href": "http://stock.jrj.com.cn/2019/12/09172728508943.shtml",
    "datetime": "2019-12-09 17:27:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业：获得药品GMP证书",
    "href": "http://stock.jrj.com.cn/2019/12/04164328489204.shtml",
    "datetime": "2019-12-04 16:43:07",
    "code": "603229"
  },
  {
    "title": "奥翔药业：获得GMP证书",
    "href": "http://stock.jrj.com.cn/2019/12/04163928489194.shtml",
    "datetime": "2019-12-04 16:39:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业：获得政府补助600万元",
    "href": "http://stock.jrj.com.cn/2019/12/02160328478018.shtml",
    "datetime": "2019-12-02 16:03:48",
    "code": "603229"
  },
  {
    "title": "奥翔药业前三季度盈利5028万 同比增长55%",
    "href": "http://stock.jrj.com.cn/2019/10/30155728325985.shtml",
    "datetime": "2019-10-30 15:57:56",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2019年前三季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2019/10/30012028321240.shtml",
    "datetime": "2019-10-30 01:20:30",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第十三次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/10/30012028321241.shtml",
    "datetime": "2019-10-30 01:20:30",
    "code": "603229"
  },
  {
    "title": "奥翔药业使用闲置募集资金2000万元理财产品到期收回",
    "href": "http://stock.jrj.com.cn/2019/10/17205228263697.shtml",
    "datetime": "2019-10-17 20:52:15",
    "code": "603229"
  },
  {
    "title": "奥翔药业：布罗佐喷钠研发项目进入临床试验Ⅱ期",
    "href": "http://stock.jrj.com.cn/2019/10/14162128243505.shtml",
    "datetime": "2019-10-14 16:21:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业使用3000万元闲置募集资金购买保本型理财产品",
    "href": "http://stock.jrj.com.cn/2019/09/18181028149216.shtml",
    "datetime": "2019-09-18 18:10:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2019年半年度主要财务指标",
    "href": "http://stock.jrj.com.cn/2019/08/28231028051839.shtml",
    "datetime": "2019-08-28 23:10:08",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第十二次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/08/28231028051840.shtml",
    "datetime": "2019-08-28 23:10:08",
    "code": "603229"
  },
  {
    "title": "奥翔药业归母净利润增长31% 积极研发促进发展",
    "href": "http://stock.jrj.com.cn/2019/08/28171528050141.shtml",
    "datetime": "2019-08-28 17:15:03",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2019年第一次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2019/08/26233028036365.shtml",
    "datetime": "2019-08-26 23:30:19",
    "code": "603229"
  },
  {
    "title": "奥翔药业拟签订新药临床试验相关的服务合同 合同价格为2691万元",
    "href": "http://stock.jrj.com.cn/2019/08/11171527958794.shtml",
    "datetime": "2019-08-11 17:15:09",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第十一次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/08/09221027955921.shtml",
    "datetime": "2019-08-09 22:10:11",
    "code": "603229"
  },
  {
    "title": "奥翔药业：关于召开2019年第一次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2019/08/09221027955922.shtml",
    "datetime": "2019-08-09 22:10:11",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2018年年度权益分派实施公告",
    "href": "http://stock.jrj.com.cn/2019/06/06093027670705.shtml",
    "datetime": "2019-06-06 09:30:19",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2018年年度股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2019/05/06220027531295.shtml",
    "datetime": "2019-05-06 22:00:05",
    "code": "603229"
  },
  {
    "title": "奥翔药业2019年第一季度净利778万元 董事长郑志国持有公司股份9598万股",
    "href": "http://stock.jrj.com.cn/2019/04/25113027481114.shtml",
    "datetime": "2019-04-25 11:30:31",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2019年第一季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2019/04/25075027478940.shtml",
    "datetime": "2019-04-25 07:50:16",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第九次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/04/25075027478941.shtml",
    "datetime": "2019-04-25 07:50:16",
    "code": "603229"
  },
  {
    "title": "奥翔药业：一季度净利778万元 同比增长287%",
    "href": "http://stock.jrj.com.cn/2019/04/24162627474866.shtml",
    "datetime": "2019-04-24 16:26:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业：关于召开2018年年度股东大会的通知",
    "href": "http://stock.jrj.com.cn/2019/04/11230027369345.shtml",
    "datetime": "2019-04-11 23:00:02",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第八次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/04/11230027369344.shtml",
    "datetime": "2019-04-11 23:00:02",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2018年年度主要财务指标",
    "href": "http://stock.jrj.com.cn/2019/04/11230027369343.shtml",
    "datetime": "2019-04-11 23:00:01",
    "code": "603229"
  },
  {
    "title": "奥翔药业去年净利4386万同比减17% 董事长郑志国年薪28万元",
    "href": "http://stock.jrj.com.cn/2019/04/11225827369434.shtml",
    "datetime": "2019-04-11 22:58:13",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2018年前三季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2018/10/30234025282144.shtml",
    "datetime": "2018-10-30 23:40:31",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第七次会议决议公告",
    "href": "http://stock.jrj.com.cn/2018/10/30234025282143.shtml",
    "datetime": "2018-10-30 23:40:31",
    "code": "603229"
  },
  {
    "title": "奥翔药业：通过美国FDA现场检查",
    "href": "http://stock.jrj.com.cn/hotstock/2018/10/22080025236275.shtml",
    "datetime": "2018-10-22 08:00:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业：通过美国FDA现场检查",
    "href": "http://stock.jrj.com.cn/2018/10/19163025228670.shtml",
    "datetime": "2018-10-19 16:30:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2018年半年度主要财务指标",
    "href": "http://stock.jrj.com.cn/2018/08/29232025022158.shtml",
    "datetime": "2018-08-29 23:20:20",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第六次会议决议公告",
    "href": "http://stock.jrj.com.cn/2018/08/29232025022159.shtml",
    "datetime": "2018-08-29 23:20:20",
    "code": "603229"
  },
  {
    "title": "[奥翔药业]台州市委、临海市委领导莅临公司调研",
    "href": "http://stock.jrj.com.cn/2018/08/29000025021672.shtml",
    "datetime": "2018-08-29 00:00:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2018年第一次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2018/07/06001024776361.shtml",
    "datetime": "2018-07-06 00:10:04",
    "code": "603229"
  },
  {
    "title": "奥翔药业：关于召开2018年第一次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2018/06/12214024670852.shtml",
    "datetime": "2018-06-12 21:40:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第五次会议决议公告",
    "href": "http://stock.jrj.com.cn/2018/06/12214024670851.shtml",
    "datetime": "2018-06-12 21:40:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2017年年度股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2018/05/04005024489648.shtml",
    "datetime": "2018-05-04 00:50:01",
    "code": "603229"
  },
  {
    "title": "奥翔药业：关于首次公开发行部分限售股上市流通的公告",
    "href": "http://stock.jrj.com.cn/2018/05/02235024483323.shtml",
    "datetime": "2018-05-02 23:50:03",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2017年年度主要财务指标",
    "href": "http://stock.jrj.com.cn/2018/04/11075024372263.shtml",
    "datetime": "2018-04-11 07:50:04",
    "code": "603229"
  },
  {
    "title": "奥翔药业：第二届董事会第二次会议决议公告",
    "href": "http://stock.jrj.com.cn/2018/04/11075024372265.shtml",
    "datetime": "2018-04-11 07:50:04",
    "code": "603229"
  },
  {
    "title": "奥翔药业：关于召开2017年年度股东大会的通知",
    "href": "http://stock.jrj.com.cn/2018/04/11075024372264.shtml",
    "datetime": "2018-04-11 07:50:04",
    "code": "603229"
  },
  {
    "title": "奥翔药业：2016年度股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2017/06/26221022658076.shtml",
    "datetime": "2017-06-26 22:10:09",
    "code": "603229"
  },
  {
    "title": "龙虎榜:佛山暴力南国置业终被埋 赵老哥反包奥翔药业",
    "href": "http://stock.jrj.com.cn/hotstock/2017/06/01215622562561.shtml",
    "datetime": "2017-06-01 21:56:08",
    "code": "603229"
  },
  {
    "title": "奥翔药业等3只新股5月9日上市",
    "href": "http://stock.jrj.com.cn/2017/05/08162122444401.shtml",
    "datetime": "2017-05-08 16:21:00",
    "code": "603229"
  },
  {
    "title": "奥翔药业中签号出炉 共3.6万个",
    "href": "http://stock.jrj.com.cn/2017/04/28003322399292.shtml",
    "datetime": "2017-04-28 00:33:35",
    "code": "603229"
  },
  {
    "title": "大客户流失日企撑腰 奥翔药业生产不看订单靠心算",
    "href": "http://stock.jrj.com.cn/ipo/2017/04/26142422388435.shtml",
    "datetime": "2017-04-26 14:24:00",
    "code": "603229"
  },
  {
    "title": "新股：奥翔药业和鸣志电器申购",
    "href": "http://stock.jrj.com.cn/ipo/2017/04/26063522384604.shtml",
    "datetime": "2017-04-26 06:35:31",
    "code": "603229"
  },
  {
    "title": "奥翔药业、鸣志电器申购指南",
    "href": "http://stock.jrj.com.cn/ipo/2017/04/26063522384603.shtml",
    "datetime": "2017-04-26 06:35:09",
    "code": "603229"
  },
  {
    "title": "奥翔药业等两新股4月26日申购指南",
    "href": "http://stock.jrj.com.cn/ipo/2017/04/25140822380706.shtml",
    "datetime": "2017-04-25 14:08:53",
    "code": "603229"
  }
]